HMG-coA reductase inhibitors: Lipid-lowering and beyond

Esther Lutgens, Mat J.A.P. Daemen

Research output: Contribution to journalReview articlepeer-review


3-Hydroxy 3-methylglutaryl coenzyme A (HMG-coA) reductase inhibitors (statins) are the primary treatment in the management of atherosclerotic vascular disease. The benefits of statin treatment are believed to result from their capacity to lower LDL-cholesterol (LDL-C). However, lowering cholesterol alone cannot explain all of the beneficial effects of statin treatment. Recent findings suggest that statins invoke a generalized anti-inflammatory action.

Original languageEnglish (US)
Pages (from-to)189-194
Number of pages6
JournalDrug Discovery Today: Therapeutic Strategies
Issue number2
StatePublished - Oct 2004

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'HMG-coA reductase inhibitors: Lipid-lowering and beyond'. Together they form a unique fingerprint.

Cite this